1. Brazil Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Fleury SA

Fleury SA

27.89
BRL
-0.19
(-0.68%)
1.13EPS
13.75P/E
8.71BMarket Cap
Nov 05Next Earn
Fleury SA
B3:FLRY3F
(B3)

Recent

price

27.89

P/E

ratio

13.75

div

yld

1.71%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
BRL
3.13
3.92
4.53
5
5.06
5.72
6.29
7.15
7.97
8.65
8.83
11.64
13.83
13.36
14.1
15.21
15.59
Revenue per Share
0.47
0.35
0.32
0.18
0.26
0.32
0.69
0.96
0.99
0.93
0.76
1.05
0.95
0.87
1.13
1.12
1.16
Basic EPS, GAAP
0.19
-0.32
0.01
0.19
0.51
0.78
1.07
0.7
1.12
1.56
1.37
1.82
1.78
2.12
2.65
2.99
2.89
Free Cash Flow per Basic Share
- -
0.09
0.1
0.25
0.6
0.05
1.15
0.39
0.91
0.92
0.68
0.89
1.05
1.05
0.63
0.94
0.48
Dividend per Share
3.63
4.93
5.15
5.1
4.75
4.99
4.61
5.1
5.22
5.24
5.2
5.49
6.97
9.33
9.72
9.18
9.53
Book Value per Share
2.47
0.35
0.53
0.47
0.12
0.43
0.04
0.51
0.36
-0.48
-0.83
-2.21
-1.24
-1.33
-1.06
-1.79
-1.33
Tangible Book Value per Share
278
287
331
331
331
331
333
333
334
336
336
333
323
484
545
545
545
Basic Weighted Avg Shares
872
1,126
1,502
1,657
1,679
1,895
2,096
2,383
2,664
2,905
2,972
3,873
4,463
6,471
7,685
8,291
8,499
Sales/Revenue/Turnover
19.35
11.88
14.31
10.58
11.58
12.85
16.02
19.97
18.74
20.07
17.03
18.33
17.17
15.35
16.04
14.97
15.22
Operating Margin (%)
33
59
100
109
114
122
145
143
189
320
358
389
455
675
780
900
921
Depreciation Expense
130
101
107
61
86
107
229
321
332
312
257
350
308
424
616
613
635
Net Income, GAAP
33.44
24.52
31.63
45
40.25
37.76
22.29
25.05
26.5
26.72
24.59
29.15
23.84
20.8
23.24
20.78
20.31
Effective Tax Rate (%)
14.92
8.94
7.1
3.69
5.11
5.66
10.91
13.45
12.44
10.75
8.65
9.04
6.9
6.55
8.02
7.39
7.47
Profit Margin (%)
650
459
419
794
752
715
524
628
810
738
770
536
1,157
1,117
2,633
2,176
2,475
Working Capital
55
553
472
911
961
802
684
746
1,049
2,039
2,112
2,444
3,142
3,661
4,894
4,721
4,709
LT Debt
1,012
1,632
1,706
1,689
1,573
1,655
1,536
1,707
1,750
1,759
1,751
1,854
2,701
5,111
5,375
5,096
5,278
Total Equity
10.65
6.41
6.61
3.85
4.46
5.63
10.58
13.93
12.75
11.53
8.5
10.1
9.89
9.15
9.06
9.07
9.25
Return on Invested Capital (%)
12.54
7.05
6.39
4.41
5.78
7.21
13.08
15.35
13.53
11.86
8.58
10.51
11.12
10.23
10.41
11.38
11.53
Return on Capital (%)
14.05
7.61
6.39
3.6
5.26
6.65
14.34
19.78
19.19
17.8
14.64
19.46
13.6
10.91
11.88
11.91
12.2
Return on Common Equity (%)

Capital Structure

BRL

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
672
551
648
LT Borrowings
3,898
3,798
3,798
LT Finance Leases
935
922
911
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
545
545
544
Market Capitalization
8,878
8,230
8,709

Working Capital

BRL

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
4,864
4,421
4,650
Cash, Cash Equivalents & STI
2,513
2,162
2,150
Accounts Receivable, Net
1,911
1,747
2,006
Inventories
155
181
151
Total Current Liabilities
2,201
2,246
2,176
Payables & Accruals
- -
- -
- -
ST Debt
672
551
648
Deferred Revenue
- -
- -
- -

Growth Rates

BRL

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.73%
28.15%
-5.18%
Free Cash Flow
25.06%
31.75%
12.85%
Net Income, GAAP
23.98%
21.33%
-0.54%
Sales/Revenue/Turnover
16.46%
23.44%
7.89%
Total Cash Common Dividend
242.55%
22.25%
49.42%

Quarterly Revenue

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,904
1,978
1,963
1,839
7,685
2025
2,015
2,025
2,191
2,061
8,291
2026
2,223
- -
- -
- -
- -

Quarterly Earnings Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.31
0.32
0.35
0.15
1.13
2025
0.33
0.28
0.34
0.18
1.12
2026
0.37
- -
- -
- -
- -

Quarterly Dividends Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.15
- -
0.48
0.63
2025
- -
- -
- -
0.48
0.94
2026
- -
- -
- -
- -
- -
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Fleury S.A. (FLRY3.SA) operates as a leading provider of diagnostic medicine services in Brazil, offering clinical analysis, diagnostic imaging, fertility treatments, and infusions through an integrated network of patient service centers and hospital operations. Founded in 1926 and headquartered in São Paulo, the company serves premium and mid-tier customers primarily in social classes A and B across eight Brazilian states and the Distrito Federal, utilizing brands such as Fleury, Clínica Felippe Mattoso, Weinmann, a+, Diagnoson a+, Labs a+, Serdil, IRN, and others from its integrated portfolio. Its services encompass high-complexity laboratory testing, imaging diagnostics including magnetic resonance and computed tomography, women's health solutions, and support for partner laboratories nationwide. Recent strategic expansions include the 2023 business combination with Grupo Pardini, which enhanced geographic coverage particularly in Minas Gerais and boosted annual revenues by approximately 45% to R$6.96 billion in 2024; acquisitions of Hemolab in Alagoas for R$39.5 million in June 2025; Laboratorio Sao Lucas in Rio Claro with R$24 million revenue for R$34 million; and Femme with 12 units and R$287 million revenue for R$207.5 million to strengthen mid-tier and women's health segments in São Paulo during 2025.